Beyond Keytruda: Merck’s Oncology Pipeline Expansion Through M&A
Is Merck ready to face the looming patent cliff? Impact of Inflation Reduction Act (IRA) on Keytruda Inflation Reduction Act (IRA) was passed in 2022
Is Merck ready to face the looming patent cliff? Impact of Inflation Reduction Act (IRA) on Keytruda Inflation Reduction Act (IRA) was passed in 2022
With the recent approval of the first two interchangeable biosimilars to Amgen’s PROLIA® and XGEVA® by the US FDA in March 2024, the overall count
Pembrolizumab, a monoclonal antibody marketed under the brand name Keytruda®, was Merck & Co’s highest-grossing product in FY 2023 with sales of about 25 billion
Following up on our previous post on looming biosimilar approvals over Eylea®(Aflibercept), on March 4, Biocon Biologics Limited (BBL), a subsidiary of Biocon Limited, announced
Secukinumab, an IL-17A antagonist, is marketed by Novartis under the brand name Cosentyx®. In 2023, Cosentyx® observed the sales of 5 billion dollars, inclusive of
Eliquis to face generic competition in late 2026? Bristol Myers Squibb (BMS) and Pfizer’s oral blood thinner – Eliquis® (Apixaban) was approved in the United
Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.
Copyright 2023 All right reserved by WSLI. Designed by Webpeckers.